357613-17-3

Upstream product

• 127978-71-6 2-hydroxymethyl-5-[(4-methoxybenzyl)oxy]pyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 824-94-2 p-methoxybenzyl chloride 
• 357613-25-3 5-[(4-methoxybenzyl)oxy]-2-methylpyridine 

Downstream Products

• 357613-19-5 (S)-(+)-N-((1E)-{5-[(4-methoxybenzyl)oxy]-2-pyridinyl}methylidene)-4-methylbenzenesulfinamide 
• 357613-21-9 (S_S,R)-(+)-methyl 3-{5-[(4-methoxybenzyl)oxy]-2-pyridinyl}-3-{[(4-methylphenyl)sulfinyl]amino}propanoate 
• 917910-83-9 C₁₄H₁₄N₂O₃ 
• 635324-47-9 (4-{[(5-benzyloxypyridin-2-yl-methyl)amino]methyl}-4-fluoropiperidin-1-yl)(3-chloro-4-fluorophenyl)methanone 

Relevant academic research and scientific papers

Niacin receptor agonists, compositions containing such compounds and methods of treatment

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Synthesis of (R)-(+)-methyl 3-amino-3-(5-hydroxy-2-pyridinyl)propanoate, an analog of L-azatyrosine

A concise asymmetric synthesis of (R)-(+)-methyl 3-amino-3-(5-hydroxy-2-pyridinyl)propanoate 2, a β-amino acid analog of L-azatyrosine 1 starting from the commercially available (-)-Andersen reagent (-)-3 in good overall yield is described.